Item 2.01. Completion of Acquisition or Disposition of Assets.
On October 10, 2018 (the Closing Date), the Company completed the Acquisition. Pursuant to the terms of the Rule 2.7 Announcement, the Vernalis shareholders are entitled to receive 0.062 per share in cash. The Company will pay approximately $42.3 million for Vernalis, offset by approximately $32 million of net cash on hand at Vernalis, after deal costs. Vernalis is a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing collaborations.
The foregoing description of the Acquisition is qualified in its entirety by reference to the Rule 2.7 Announcement, a copy of which was filed as Exhibit 2.1 to the Ligands Current Report on Form 8-K filed with the SEC on August 9, 2018.
Foreign Exchange Conversion
Amounts converted from pound sterling to U.S. dollars have been converted at the prevailing exchange rate as of the date of this announcement.
Item 9.01. Financial Statements and Exhibits.
